Treatment for Neonatal Abstinence Syndrome Using Nonpharmacological Interventions
American Journal of Perinatology · 01.12.2024 · 41 (16) · 2198-2205
DOI: 10.1055/s-0044-1786744 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift American Journal of Perinatology, erschienen am 01.12.2024. Verfasst von Tonya W Robinson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Louisville School of Medicine, Louisville, Kentucky. Hauptthemen laut MEDLINE: Neonatal Abstinence Syndrome, Intensive Care Units, Neonatal, Length of Stay. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Management of neonatal abstinence syndrome includes nonpharmacological interventions, but their effectiveness may not be verified before implemented. The objective of this study is to evaluate the effectiveness of a type of bassinet in the treatment of infants with neonatal abstinence syndrome. Study Design This is a retrospective observational cohort study. Study setting involved a 24-bed open-bay Level III neonatal intensive care unit located in a metropolitan academic trauma facility. Participant inclusion criteria involved prenatally opioid-exposed infants ≥ 35 weeks with confirmed maternal opioid urine toxicology, required pharmacological treatment for withdrawal symptoms, and were admitted to the neonatal intensive care unit. Three subsets of study participants were analyzed over three different time periods: Group 1 were infants admitted during 2019 without nonpharmacological intervention, Group 2 who were admitted from September 2021 to February 2022 and received nonpharmacological interventions, and Group 3 included those admitted from February 2022 to March 2023 who received the same interventions as Group 2 but were managed in bassinets being used in other local facilities for neonatal abstinence syndrome.
Results
Group 3 had significant increases in length of stay compared with Group 1 (p = 0.006) and Group 2 (p = 0.013). Group 3 had a significantly greater length of treatment than Group 1 (p = 0.041) and a significantly higher total mg/kg morphine exposure than Group 1 (p = 0.006).
Conclusion
Addition of the bassinet for nonpharmacological management of infants with neonatal abstinence syndrome appeared to prolong length of stay, length of treatment, and increase total mg/kg morphine exposure. As a retrospective nonrandomized study, weakness of low certainty of causality is of concern but findings strongly warrant further research before devices such as the bassinet used in this study are adopted for routine neonatal abstinence syndrome care. Key Points
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, University of Louisville School of Medicine, Louisville, Kentucky.
- Center for Women and Infants, University of Louisville Hospital, Louisville, Kentucky.
ORCID-Profile: Tonya W Robinson
Zitieren
APA
Robinson, T. W., Stikes, R., Sorrell, J., Gater, A., Booth, A. T., Gardner, A., Greenwell, C., Businger, S., Low, R., & Petrie, R. (2024). Treatment for Neonatal Abstinence Syndrome Using Nonpharmacological Interventions. American Journal of Perinatology, 41(16), 2198-2205. https://doi.org/10.1055/s-0044-1786744
Vancouver
Robinson TW, Stikes R, Sorrell J, Gater A, Booth AT, Gardner A, et al. Treatment for Neonatal Abstinence Syndrome Using Nonpharmacological Interventions. American Journal of Perinatology. 2024;41(16):2198-2205. doi:10.1055/s-0044-1786744
BibTeX
@article{Robinson2024,
author = {Robinson, Tonya W and Stikes, Reetta and Sorrell, Jaki and Gater, Amanda and Booth, Adam T and Gardner, Amanda and Greenwell, Colleen and Businger, Shannon and Low, Ryan and Petrie, Rachael},
title = {Treatment for Neonatal Abstinence Syndrome Using Nonpharmacological Interventions},
journal = {American Journal of Perinatology},
year = {2024},
volume = {41},
number = {16},
pages = {2198--2205},
doi = {10.1055/s-0044-1786744}
}
EUVIMED